Technology
Health
Biotechnology

Unum Therapeutics

$4.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.35 (-7.95%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell UMRX and other stocks, options, ETFs, and crypto commission-free!

About

Unum Therapeutics Inc. Common Stock, also called Unum Therapeutics, is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Read More The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Employees
53
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
131.67M
Price-Earnings Ratio
Dividend Yield
Average Volume
238.46K
High Today
$4.47
Low Today
$3.95
Open Price
$4.37
Volume
118.25K
52 Week High
$17.66
52 Week Low
$3.60

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Cancer Prevention
Pharmaceutical

News

MarketBeatFeb 27

Stock Price, News, & Analysis for Unum Therapeutics

Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company's product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to tre...

24
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.